Contact Us

    • 1-631-466-5530
      44-207-097-1828
    • 1-631-207-8356
    • 45-1 Ramsey Road, Shirley, NY 11967, USA
    • Global Locations

Oncolytic Viruses in Osteosarcoma Treatment

Osteosarcoma is a type of bone cancer that usually develops in the osteoblast, cells accounting for ~20% of all primary bone tumors. Oncolytic virus (OV) therapy is the use of a replication-competent virus for the treatment of cancer. OVs are non-pathogenic live viruses, which have intrinsic cancer-selective killing activity, or can be engineered to express attenuating genes or arming genes. OV therapy has shown success in preclinical and clinical testing as a novel cancer treatment modality with high safety profiles and low off-target toxicities.

Osteosarcoma

Osteosarcoma (OS), also called osteogenic sarcoma (OGS), is the most common malignant bone tumor. Osteosarcoma is thought to arise from primitive mesenchymal bone-forming cells, and its histologic hallmark is the exhibition of osteoblastic differentiation and the production of malignant osteoid. OS is most prevalent in teenagers and young adults within the fastest growing areas of the long bones. Symptoms of OS mainly include swelling or pain near a bone or joint, bone injury or bone break for no clear reason. Traditional treatment, involving chemotherapy, surgery and, sometimes, radiation therapy, usually shows a limited curative effect. It is urgent to develop novel therapeutic strategies.

Osteosarcoma (OS). Fig.1 Osteosarcoma (OS).

Oncolytic Viruses Therapy in Osteosarcoma

Because of the complex genetic make-up, OS is a challenging malignancy to identify novel targets for therapy. OV therapy may be a potential therapeutic option, not dependent on the consistent expression of a single target.

Targets for oncolytic virotherapy in osteosarcoma. Fig.2 Targets for oncolytic virotherapy in osteosarcoma. (Hingorani, 2014)

In addition to the viruses mentioned above, several other viruses are being analyzed as oncolytic agents for the treatment of osteosarcoma, including reovirus, Semliki forest virus (SFV), vesicular stomatitis virus (VSV), measles virus, and Newcastle disease virus (NDV). They present either naturally tumor-selective or can be modified to specifically target and eliminate tumor cells.

Oncolytic Viruses Engineering

With recent improvements in modern genetic engineering techniques, oncolytic viruses can be manipulated to alter the capsid to reduce pathogenicity and immunogenicity, to the secret antibody to boost the anti-tumor immune response, to express cytokine/chemokine to attract immune cells migration to the tumor site, and even to be loaded with immune checkpoint inhibitors. For example, we can choose tumor-specific promoters (TSPs) for conditionally replicating to improve the specificity of OVs. We can engineer a virus that relies on a pathway that is upregulated in tumor cells for successful tumor infection thereby rendering the virus incapable of infecting healthy tissue.

Reference

  1. Hingorani, P.; et al. Oncolytic viruses for potential osteosarcoma therapy. Current Advances in Osteosarcoma. Springer, Cham, 2014: 259-283.

Please feel free to contact us for a quote and further discussion with our scientists.

All services and products are for lab research only, not for any clinical use.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved